Abstract 1995
Background
Anti-PD-1 and anti-CTLA-4 immunotherapies have become the standard of care for metastatic melanoma. However, the majority of patients develop resistance to therapy. Macrophages are abundant cells in tumours, but their role in immunotherapy response and resistance is largely unknown. This study investigated the role of macrophages in anti-PD-1 +/- CTLA-4 response in stage IV melanoma patients.
Methods
Transcriptomic and multiplex immunohistochemistry (mIHC) immune profiling were performed on formalin-fixed paraffin embedded tissue pre-treatment biopsies from advanced melanoma patients treated with anti-PD-1 (n = 19) or anti-PD-1 + anti-CTLA-4 (n = 10). Response and progression-free survival were assessed using RECIST criteria. Using tumour dissociates, mass cytometry was used to characterize macrophages in detail.
Results
Although there was no significant difference in CD68+ macrophages between responding and non-responding patients, responding patients had a significantly higher intratumoral density of CD14+ CD68+ CD16+ macrophages compared to non-responders at baseline (median= 192 versus 23; p = 0.006). Using mIHC, patients were classified into high/low CD16+ macrophages and differential RNA expression analysis was performed. CD16+ high macrophage tumours displayed increased expression of genes related to T cell activation (TIGIT, LAG3, ICOS, PDCD1, FASLG and TBX21), MHC class I presentation (TAP1, UBD, PSMB10 and B2M) and chemokine + cytokine activity (CXCL13, CXCL10, CXCL11, CXCL9, CXCR6 and CXCR3). Using mass cytometry, we determined that CD16+ macrophages are CD13+ HLA-DR+, ICOS+ CD86+/- LAG3- GITR- TIGIT-. Multivariate analysis showed that low LDH, low melanoma substage and the presence of high CD16+ macrophages were associated with a significantly better overall response rate (OR = 14; p = 0.011) and progression free survival (HR = 0.15; p = 0.016), but not overall survival (HR = 0.22; p = 0.068).
Conclusions
Presence of CD68+ CD14+ CD16+ macrophages in pre-treatment melanoma combined with low LDH and low melanoma substage strongly correlates with response and survival of advanced melanoma patients treated with immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
James Wilmott.
Funding
National Health and Medical Research Council (NHMRC).
Disclosure
M.S. Carlino: Advisory / Consultancy: Amgen; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pierre Fabre. A.M. Menzies: Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. G.V. Long: Advisory / Consultancy: Amgen; Advisory / Consultancy: Array; Advisory / Consultancy: BMS; Advisory / Consultancy: Merck MSD; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Advisory / Consultancy: Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract
2655 - The K-BASKET trial: A prospective phase II biomarker-driven multiple basket trial in Korean solid cancer patients.
Presenter: Seul Kim
Session: Poster Display session 3
Resources:
Abstract
5938 - Cambridge Liquid biopsy “CALIBRATION” study: Can changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients with advanced oesophageal cancer receiving MEDI4736?
Presenter: Constanza Linossi
Session: Poster Display session 3
Resources:
Abstract
3799 - Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases
Presenter: Andrea Mafficini
Session: Poster Display session 3
Resources:
Abstract
4647 - Microsatellite Instability Testing and Lynch Syndrome Screening For Colorectal Cancer Patients Through Tumor Sequencing
Presenter: Li Liu
Session: Poster Display session 3
Resources:
Abstract
3231 - "Liquid Withdarw" technique in CT-guided cutting needle lung biopsy: decreased incidence of complications and increased tissue amount for lung cancer molecular testing.
Presenter: Xue Wang
Session: Poster Display session 3
Resources:
Abstract
3282 - WGS Implementation in standard cancer Diagnostics for Every cancer patient (WIDE)
Presenter: Paul Roepman
Session: Poster Display session 3
Resources:
Abstract
5905 - Known and unknown gene fusion detection capabilities of solid tumor laboratories conducting next generation sequencing in 6 countries
Presenter: Steph Finucane
Session: Poster Display session 3
Resources:
Abstract
4238 - Clinical and Analytical Accuracy of a 523 Gene Panel Next-Generation Sequencing (NGS) Assay on Formalin-Fixed Paraffin-Embedded (FFPE) Solid Tumor Samples
Presenter: Ina Deras
Session: Poster Display session 3
Resources:
Abstract
2493 - Methylation analysis of MLH1 using droplet digital PCR and methylation sensitive restriction enzyme.
Presenter: Celine De Rop
Session: Poster Display session 3
Resources:
Abstract